Literature DB >> 30009716

Overexpression of Hepassocin in Diabetic Patients with Nonalcoholic Fatty Liver Disease May Facilitate Increased Hepatic Lipid Accumulation.

Ghada Abdelmoemen1, Samy Abdelkader Khodeir2, Ahmed Nabil Zaki1, Maha Kassab1, Sabry Abou-Saif3, Sherief Abd-Elsalam3.   

Abstract

BACKGROUND & AIMS: Insulin resistance is the real determinant of both Nonalcoholic fatty liver disease (NAFLD) and diabetes, and can facilitate the accumulation of triglycerides in the liver. Overexpression of hepassocin (HPS) increased the accumulation of hepatic fat and NAFLD activity scores (NAS) in mice. The aim of this study was to investigate the relationship between hepassocin and steatosis of the liver in diabetic patients with or without NAFLD in humans.
METHODS: The study enrolled 60 patients plus 20 healthy controls that were divided into 4 groups: Group I: included 20 patients who were diagnosed as diabetes mellitus type 2, Group II: included 20 patients who were diagnosed as nonalcoholic fatty liver disease (NAFLD), Group III: included 20 patients who were diagnosed as diabetes type 2 and NAFLD, and Group IV (control group): included 20 healthy person or controls who were matched in age and sex with patients group. All patients and controls were subjected to full history taking, thorough clinical examination, laboratory investigations including measurement of serum hepassocin in peripheral blood by ELISA technique.
RESULTS: There was a significant overexpression of serum hepassocin in patients with type 2 diabetes and NAFLD patients (Group 3) more than diabetic patients (Group 1) and even more than non-alcoholic fatty liver disease (Group 2).
CONCLUSION: This study provides evidence that increased HPS may facilitate increased hepatic lipid accumulation with NAFLD and type 2 diabetes. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  NAFLD; Serum hepassocin; diabetes mellitus; insulin resistance; metabolic syndrome; nonalcoholic fatty liver disease.

Mesh:

Substances:

Year:  2019        PMID: 30009716     DOI: 10.2174/1871530318666180716100543

Source DB:  PubMed          Journal:  Endocr Metab Immune Disord Drug Targets        ISSN: 1871-5303            Impact factor:   2.895


  8 in total

Review 1.  Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC.

Authors:  Hyunmi Kim; Da Som Lee; Tae Hyeon An; Hyun-Ju Park; Won Kon Kim; Kwang-Hee Bae; Kyoung-Jin Oh
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

2.  Presence of diabetic retinopathy is lower in type 2 diabetic patients with non-alcoholic fatty liver disease.

Authors:  Meng Zhang; Li Li; Jing Chen; Bei Li; Yutao Zhan; Chuan Zhang
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

3.  A Non-Invasive Prediction Model for Non-Alcoholic Fatty Liver Disease in Adults with Type 2 Diabetes Based on the Population of Northern Urumqi, China.

Authors:  Mingyue Xue; Xiaoping Yang; Yuan Zou; Tao Liu; Yinxia Su; Cheng Li; Hua Yao; Shuxia Wang
Journal:  Diabetes Metab Syndr Obes       Date:  2021-02-02       Impact factor: 3.168

Review 4.  Implication of the hepatokine, fibrinogen-like protein 1 in liver diseases, metabolic disorders and cancer: The need to harness its full potential.

Authors:  Xi-Hua Liu; Lian-Wen Qi; Raphael N Alolga; Qun Liu
Journal:  Int J Biol Sci       Date:  2022-01-01       Impact factor: 6.580

Review 5.  Beyond the Liver: Liver-Eye Communication in Clinical and Experimental Aspects.

Authors:  Tian-Hao Yuan; Zhen-Sheng Yue; Guo-Heng Zhang; Lin Wang; Guo-Rui Dou
Journal:  Front Mol Biosci       Date:  2021-12-24

6.  A combined association of serum uric acid, alanine aminotransferase and waist circumference with non-alcoholic fatty liver disease: a community-based study.

Authors:  Min Wang; Minxian Wang; Ru Zhang; Liuxin Zhang; Yajie Ding; Zongzhe Tang; Haozhi Fan; Hongliang Wang; Wei Zhang; Yue Chen; Jie Wang
Journal:  PeerJ       Date:  2022-03-04       Impact factor: 2.984

7.  Recombinant Human HPS Protects Mice and Nonhuman Primates from Acute Liver Injury.

Authors:  Yang Yang; Huali Zhai; Yue Wan; Xiaofang Wang; Hui Chen; Lihou Dong; Taoyun Liu; Guifang Dou; Chutse Wu; Miao Yu
Journal:  Int J Mol Sci       Date:  2021-11-28       Impact factor: 5.923

8.  Association of non-alcoholic fatty liver disease with diabetic retinopathy in type 2 diabetic patients: A meta-analysis of observational studies.

Authors:  Dandan Song; Chengqian Li; Zhongchao Wang; Yuhang Zhao; Baoming Shen; Wenjuan Zhao
Journal:  J Diabetes Investig       Date:  2021-02-01       Impact factor: 4.232

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.